Bayer HealthCare
Pharmaceuticals
-
Friday - May 17, 2013
Not intended for U.S. and UK Media
Bayer Submits Investigational Drug Riociguat for Patients with Chronic Thromboembolic Pulmonary Hypertension for Regulatory Approval in Japan » more
-
Thursday - May 16, 2013
Not intended for U.S. and UK Media - 49th Annual Meeting of the American Society of Clinical Oncology (ASCO):
Bayer to Present New Data Across Oncology Portfolio at ASCO 2013
First presentation of final analysis from pivotal Phase III DECISION trial of Nexavar (sorafenib) in patients with differentiated thyroid cancer presented as Plenary Abstract in Oral Abstract Session / Data presentations for three oncology products across five tumor types » more
-
Wednesday - May 15, 2013
Not intended for U.S. and UK Media
Bayer Receives U.S. FDA Approval for Cancer Treatment Xofigo® (radium 223 dichloride) Injection
New treatment for castration-resistant prostate cancer (CRPC) patients with bone metastases / Xofigo shown in a pivotal Phase III trial to significantly improve overall survival » more
-
Wednesday - May 15, 2013
Not intended for U.S. and UK Media
Bayer Initiates Phase III Trial of Regorafenib in Patients with Advanced Liver Cancer » more
-
Wednesday - May 8, 2013
Not intended for U.S. and UK Media - The American Thoracic Society International Conference 2013:
Bayer to Present Data on Pulmonary Hypertension Research at the ATS International Conference 2013 in Philadelphia
Interim Analysis from Long-Term Extension Study PATENT-2 Phase III / Hemodynamic data and clinical correlation from CHEST-1 Phase III / New Data Sets from Pivotal PATENT-1 Phase III » more
-
Tuesday - May 7, 2013
Not intended for U.S. and UK Media - Cardiovascular Disease Prevention:
Bayer HealthCare joins forces with Stroke Alliance for Europe to prevent Cardiovascular Disease
International opinion leaders raise awareness for societal burden resulting from cardiovascular disease » more
-
Monday - May 6, 2013
Not intended for U.S. and UK Media
Bayer HealthCare Presents New Incubator Model for Biotech Startup Companies in Berlin
Second CoLaborator with dedicated lab space now at Bayer HealthCare Research & Development Center in Berlin / Shared lab space for promising life science startup companies to help them get their start » more
-
Friday - May 3, 2013
Not intended for UK Media
Bayer Provides Update on Phase II/III Trial of BAY 86-6150 » more
-
Tuesday - April 16, 2013
Not intended for U.S. and UK Media
First Patient Enrolled in Global Phase III Program Evaluating Bayer’s Amikacin Inhale in Intubated and Mechanically Ventilated Patients with Gram-negative Pneumonia
Treatments to complement current standard of care urgently needed as morbidity and mortality is significant in this patient population » more
-
Wednesday - April 10, 2013
Immunotherapies against cancer:
Bayer HealthCare to broaden strategic alliance with German Cancer Research Center
Joint immunotherapy research laboratory at the National Center for Tumor Diseases (NCT) in Heidelberg / Operations at the joint laboratory scheduled to start in the middle of 2013 / Additional investments of up to €3 million per year » more
-
Monday - April 8, 2013
Not intended for U.S. and UK Media
U. S. FDA Grants Priority Review to Bayer’s Riociguat for the Treatment of two Life-Threatening Pulmonary Hypertension Indications » more
-
Friday - April 5, 2013
Not intended for U.S. and UK Media - 104th Annual Meeting American Association for Cancer Research
Bayer to Present New Data on Growing Oncology Pipeline
New Preclinical and Early Clinical Data Evaluating Innovative Compounds in Drug Development / Numerous Oral and Poster Presentations Highlight Bayer’s Advancing Oncology Portfolio » more
-
Monday - March 25, 2013
Not intended for U.S. and UK Media
Bayer’s Stivarga® (regorafenib) Tablets Approved in Japan for the Treatment of Advanced or Recurrent Colorectal Cancer » more
-
Friday - March 22, 2013
Not intended for U.S. and UK Media - Acute Coronary Syndrome (ACS)
Bayer’s Xarelto® (Rivaroxaban) Recommended for Approval in the EU for the Prevention of Atherothrombotic Events after an ACS
Xarelto 2.5 mg twice-daily (BID) demonstrated significant clinical benefit for patients with ACS when used with standard antiplatelet therapy / Complementary modes of action of Xarelto 2.5 mg BID and antiplatelet therapy have the potential to provide more complete protection against long-term clot formation / Final decision from the European Commission expected in the first half of 2013 » more
-
Friday - March 8, 2013
Not intended for U.S. and UK Media
New Pivotal Phase III Study Initiated with Bayer’s Xarelto® (Rivaroxaban) in Patients with Chronic Heart Failure and Significant Coronary Artery Disease
Low-dose rivaroxaban given fast track designation by U.S. FDA as first novel oral anticoagulant to be evaluated in this high-risk patient group » more
-
Friday - March 8, 2013
Not intended for U.S. and UK Media
Bayer Initiates Xarelto® (Rivaroxaban) Study in Patients with Non-Valvular Atrial Fibrillation Undergoing Percutaneous Coronary Intervention with Stent Placement » more
-
Thursday - March 7, 2013
Not intended for U.S. and UK Media
Bayer to collaborate with the Children’s Hospital & Research Center Oakland to fight rare blood diseases
Focus on sickle cell anemia / Bayer’s Mission Bay-based scientists to join one of the largest sickle cell programs in the U.S. » more
-
Tuesday - March 5, 2013
Not intended for U.S. and UK Media: Acute Coronary Syndrome (ACS):
U.S. FDA Issues Complete Response Letter for Bayer’s Xarelto® (Rivaroxaban) for the Reduction of Cardiovascular Events in Patients with ACS » more
-
Monday - March 4, 2013
Not intended for U.S. and UK Media - Long-term extension study of Riociguat in patients with CTEPH:
Interim results from CHEST-2 study support benefits of Bayer’s Riociguat as demonstrated in Phase III CHEST-1 study
Riociguat showed significant and sustained improvements in six minute walking distance (6MWD) and WHO functional class (FC) in patients with inoperable or residual chronic thromboembolic pulmonary hypertension (CTEPH) (1) / Riociguat showed good long-term safety profile (1) » more
-
Friday - March 1, 2013
Not intended for U.S. and UK Media - 62nd American College of Cardiology (ACC) Annual Scientific Session and Exposition:
New Data on Bayer’s Rivaroxaban Underscores Clinical Benefits of Arterial Clot Prevention in Two Major Cardiovascular Disorders
Benefits of rivaroxaban in acute coronary syndrome (ACS) highlighted in new subanalyses to be presented from Phase III ATLAS ACS 2-TIMI 51 study / Subanalysis from ROCKET AF Phase III trial to be presented, further exploring the protective benefits of rivaroxaban in stroke prevention in patients with AF / Independently, Thrombosis Research Institute (TRI) and Duke Clinical Research Institute to present data from their Registries in patients with AF, which are supported through independent research grants from Bayer and Janssen respectively » more
Copyright @ Bayer AG